Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00025233 · OUTCOME

Age at Enrollment

Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix · Source last updated 2019-07-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Baseline

Analysis population: Eligible and treated patients

Groups in this outcome

Bevacizumab

Bevacizumab 15 mg/kg IV, every 3 weeks (one cycle) until disease progression or adverse effects prohibit further therapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Bevacizumab46

Reported measurements

Source class 1

20-29 years

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Bevacizumab1Not reportedNot reportedNot reportedNot reported

30-39 years

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Bevacizumab11Not reportedNot reportedNot reportedNot reported

40-49 years

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Bevacizumab17Not reportedNot reportedNot reportedNot reported

50-59 years

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Bevacizumab12Not reportedNot reportedNot reportedNot reported

60-69 years

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Bevacizumab5Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      title
      20-29 years
    2. measurements
      1. group Id
        OG000
        value
        11
      title
      30-39 years
    3. measurements
      1. group Id
        OG000
        value
        17
      title
      40-49 years
    4. measurements
      1. group Id
        OG000
        value
        12
      title
      50-59 years
    5. measurements
      1. group Id
        OG000
        value
        5
      title
      60-69 years
denoms
  1. counts
    1. group Id
      OG000
      value
      46
    units
    Participants
groups
  1. description
    Bevacizumab 15 mg/kg IV, every 3 weeks (one cycle) until disease progression or adverse effects prohibit further therapy
    id
    OG000
    title
    Bevacizumab
param Type
COUNT_OF_PARTICIPANTS
population Description
Eligible and treated patients
reporting Status
POSTED
time Frame
Baseline
title
Age at Enrollment
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice